
    
      Post-marketing study to evaluate the effect of impaired hepatic function on the
      pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite and on the safety of
      FerriproxÂ® in subjects with mild and moderate hepatic impairment as compared to healthy
      volunteers.
    
  